Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

PCBs are synthetic chemicals once used in industry, including missile control electrical components such as display screens, ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...

As the former BeiGene gears up to battle AbbVie and J&J, shares of the new BeOne Medicines haven't been this high in four ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug Administration (FDA) has ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...